Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBV 002
- Development stage
- Preclinical
- Lead developer
- Revascular
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
RBV 002 is a **preclinical allogeneic cell therapy** from Revascular being developed for **Hemophilia A**. The product is based on **CD157-positive vascular endothelial stem cells**, a regenerative vascular cell platform intended to restore or improve endothelial and vascular function. No specific molecular target, administration route, or explicit mechanism of action has been publicly disclosed, but the therapeutic rationale appears to be repair or replacement of dysfunctional vascular endothelial biology using donor-derived endothelial stem cells.
- Other names
- allogeneic vascular endothelial stem cells CD157+
Beyond the preview
Go deeper on RBV 002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBV 002.